Trials Sponsors Conditions Drugs Pricing

Conditions

Hodgkin Lymphoma in Remission

Keywords

epigenetic markers

Outcome Measures

Primary Outcomes (2)

evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
Determine the biological age of patients
through study completion, an average of 2 year
DNA methylation (methylation rate)
Determine the biological age of patients
through study completion, an average of 2 year

Secondary Outcomes (2)

evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
through study completion, an average of 2 year
DNA methylation (methylation rate)
through study completion, an average of 2 year

Study Arms (1)

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

EXPERIMENTAL

in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV

Other: peripheral blood sampling

Interventions

peripheral blood samplingOther

It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, 40138, Italy

RECRUITING

Pier Luigi Zinzani, MDCONTACT+390512144042 pierluigi.zinzani@unibo.it

Cinzia Pellegrini, MDCONTACT+390512143680 cinzia.pellegrini@aosp.bo.it

Pier Luigi Zinzani, MDPRINCIPAL INVESTIGATOR

Study Officials

Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+390512144042 pierluigi.zinzani@unibo.it

Cinzia Pellegrini, MD

CONTACT

+390512103680

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: HEALTH SERVICES RESEARCH
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 1, 2024

First Posted

January 7, 2025

Study Start

November 3, 2022

Actual (reported)

Primary Completion

September 30, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Study Arms (1)

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (2)

Study Arms (1)

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations